Tags

Type your tag names separated by a space and hit enter

Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study.

Abstract

BACKGROUND

A systematic review from the Cochrane Collaboration stated that alpha-lipoic acid (ALA) may help in the management of burning mouth syndrome (BMS). Because all of the data on ALA came from a single group, it has been stressed that its effectiveness should be reproduced in other populations.

AIM

A double-blind, randomized, placebo-controlled study, including two test groups (Group A and Group B) and one control group (Group C), was carried out to evaluate the efficacy of systemic ALA (400 mg) and ALA (400 mg) plus vitamins in the treatment of BMS.

METHODS

Sixty-six patients (54 females and 12 males) were included in an 8-week trial. Symptoms were evaluated by using a visual analogue scale (VAS) and the McGill Pain Questionnaire (MPQ) at 0, 2, 4, 8 and 16 weeks.

RESULTS

Fifty-two patients (43 females and 9 males, aged 67.3+/-11.9 years) completed the study. All three groups had significant reductions in the VAS score and in the mixed affective/evaluative subscale of the MPQ; the responders' rate (at least 50% improvement in the VAS score) was about 30%. No significant differences were observed among the groups either in the response rate or in the mean latency of the therapeutic effect.

CONCLUSIONS

The fairly high placebo effect observed is very similar to data obtained from patients affected by atypical facial pain. This study failed to support a role for ALA in the treatment of BMS, and further investigations are needed to identify the cause of BMS in order to develop efficacious therapies.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biomedical Sciences and Human Oncology, Oral Medicine Section, University of Turin, Italy.

    , , ,

    Source

    MeSH

    Aged
    Burning Mouth Syndrome
    Double-Blind Method
    Drug Combinations
    Female
    Humans
    Male
    Middle Aged
    Pain Measurement
    Pain Threshold
    Placebo Effect
    Placebos
    Prospective Studies
    Thioctic Acid
    Treatment Failure
    Vitamin B Complex

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    18675569

    Citation

    Carbone, Mario, et al. "Lack of Efficacy of Alpha-lipoic Acid in Burning Mouth Syndrome: a Double-blind, Randomized, Placebo-controlled Study." European Journal of Pain (London, England), vol. 13, no. 5, 2009, pp. 492-6.
    Carbone M, Pentenero M, Carrozzo M, et al. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. Eur J Pain. 2009;13(5):492-6.
    Carbone, M., Pentenero, M., Carrozzo, M., Ippolito, A., & Gandolfo, S. (2009). Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. European Journal of Pain (London, England), 13(5), pp. 492-6. doi:10.1016/j.ejpain.2008.06.004.
    Carbone M, et al. Lack of Efficacy of Alpha-lipoic Acid in Burning Mouth Syndrome: a Double-blind, Randomized, Placebo-controlled Study. Eur J Pain. 2009;13(5):492-6. PubMed PMID: 18675569.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. AU - Carbone,Mario, AU - Pentenero,Monica, AU - Carrozzo,Marco, AU - Ippolito,Alessio, AU - Gandolfo,Sergio, Y1 - 2008/12/09/ PY - 2008/01/27/received PY - 2008/05/26/revised PY - 2008/06/07/accepted PY - 2008/8/5/pubmed PY - 2009/7/16/medline PY - 2008/8/5/entrez SP - 492 EP - 6 JF - European journal of pain (London, England) JO - Eur J Pain VL - 13 IS - 5 N2 - BACKGROUND: A systematic review from the Cochrane Collaboration stated that alpha-lipoic acid (ALA) may help in the management of burning mouth syndrome (BMS). Because all of the data on ALA came from a single group, it has been stressed that its effectiveness should be reproduced in other populations. AIM: A double-blind, randomized, placebo-controlled study, including two test groups (Group A and Group B) and one control group (Group C), was carried out to evaluate the efficacy of systemic ALA (400 mg) and ALA (400 mg) plus vitamins in the treatment of BMS. METHODS: Sixty-six patients (54 females and 12 males) were included in an 8-week trial. Symptoms were evaluated by using a visual analogue scale (VAS) and the McGill Pain Questionnaire (MPQ) at 0, 2, 4, 8 and 16 weeks. RESULTS: Fifty-two patients (43 females and 9 males, aged 67.3+/-11.9 years) completed the study. All three groups had significant reductions in the VAS score and in the mixed affective/evaluative subscale of the MPQ; the responders' rate (at least 50% improvement in the VAS score) was about 30%. No significant differences were observed among the groups either in the response rate or in the mean latency of the therapeutic effect. CONCLUSIONS: The fairly high placebo effect observed is very similar to data obtained from patients affected by atypical facial pain. This study failed to support a role for ALA in the treatment of BMS, and further investigations are needed to identify the cause of BMS in order to develop efficacious therapies. SN - 1532-2149 UR - https://www.unboundmedicine.com/medline/citation/18675569/Lack_of_efficacy_of_alpha_lipoic_acid_in_burning_mouth_syndrome:_a_double_blind_randomized_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1090-3801(08)00138-9 DB - PRIME DP - Unbound Medicine ER -